TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03669432

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery alone
Description: This intervention is of no interest

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: This intervention is of no interest
Study: NCT03679611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
Study: NCT03625167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with petrolatum
Description: Petrolatum is applied twice daily to the intervention arm.
Study: NCT00651417

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Organic Germanium
Description: Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets orally 3 - 5 times per day as tolerated
Study: NCT02975466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of AirQ Blocker and intubation through the device
Description: Insertion of the SGA device and evaluation of easiness of endotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of AuraGain and intubation through the device
Description: Insertion of the SGA device and evaluation of easiness of endotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of I-Gel and intubation through the device
Description: Insertion of the SGA device and evaluation of easiness of endotracheal intubation
Study: NCT01968252

Intervention type: OTHER
Intervention: Concurrent TTE and TEE
Description: All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
Study: NCT01483508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol- and procyanidins-containing drink
Description: Single oral intake of a cocoa-based dairy drink containing flavanols \[monomer\] and procyanidins \[dimers to decamers\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procyanidins-containing drink
Description: Single oral intake of a ocoa-based dairy drink containing procyanidins \[dimers to decamers\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-containing drink
Description: Single oral intake of a cocoa-based dairy drink containing flavanols \[monomers\]
Study: NCT02501057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician's Guide
Description: An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Motivational Interviewing
Description: Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Clinician's Guide
Description: An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
Study: NCT03918798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 1% Injectable Solution
Description: All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 2% Injectable Solution
Description: All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Study: NCT02968888

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk 1%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate 80

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native whey
Study: NCT02032368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Study: NCT00625911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: intravenous patient controlled analgesia, standard protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine ketamine
Description: low dose ketamine added to 2/3 standard dose of morphine
Study: NCT03054103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam + Ketamine 10 MG/ML: 0.5 ML
Description: 5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam + Ketamine 10 MG/ML: 1 ML
Description: 10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam + Normal saline
Description: Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
Study: NCT00769106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cell (CIK) treatment
Description: cytokine-induced killer cell treatment every two weeks, for 4 cycles
Study: NCT01229085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memotasone + salicylic acid
Description: mometasone 0,1% + salicylic acid 5%.
Study: NCT00004193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 2503
Study: NCT04682041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Plasma-Derived Immunoglobulin Concentrate
Description: EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care PSMAR protocol for COVID-19 patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care PSMAR protocol for COVID-19 patients.
Study: NCT03184441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Premie Pouch
Description: The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
Study: NCT01967108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: chest physiotherapy, up to one hour from extubation, in ICU patients
Study: NCT02447900

Intervention type: DEVICE
Group type: OTHER
Intervention: BioXmark
Study: NCT00265759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
Study: NCT02270736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201 Placebo
Description: NT 201 placebo matching injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: NT 201 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: NT 201 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: NT 201 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: NT 201 injection.
Study: NCT01993875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
Study: NCT01940471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: Tablet administered orally once daily
Study: NCT00627887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: extended release target dose of 300mg/day duration of one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: extended release target dose of 300mg/day duration of one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: serum concentration 0,5-0,8 mmol/L, one year duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: serum concentration 0,5-0,8 mmol/L, one year duration
Study: NCT01120392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment with Nintendo wii.
Description: Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy conventional.
Description: Conventional exercises used with the same goals for the group with wii
Study: NCT03811457

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Welgenaleucel
Description: Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
Study: NCT02591381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial Urinary Sphincter Placement
Description: The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial Urinary Sphincter Placement
Description: The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
Study: NCT00615472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
Study: NCT00904631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eraser device+ salicylic acid (5%)
Description: Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
Study: NCT00492427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: 6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.
Study: NCT01050452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole
Description: albendazole (400 mg on dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebendazole
Description: mebendazole (500 mg one dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin
Description: ivermectin (200 microgram/kg body weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole + ivermectin
Description: albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebendazole + ivermectin
Description: mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
Study: NCT01120548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation therapy
Description: The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient.
Study: NCT01001468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201
Description: Single daily dose of oral VB-201 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201
Description: Single daily dose or oral VB-201 80 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single daily dose of oral placebo
Study: NCT04133454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV-hTERT
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
Study: NCT01434589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STICA Intervention
Description: Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
Study: NCT02047136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group (on low histamine diet)
Description: 78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Well-balanced diet
Description: Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
Study: NCT02065167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured autologous Mesenchymal Cells
Description: Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
Study: NCT00753831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aurosling
Description: Silicon rod to be used in frontalis suspension surgery
Study: NCT04596020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)
Description: Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)
Description: Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
Study: NCT04568395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCIG
Description: Use a TCIG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG
Description: Use an ECIG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham control
Description: Use a sham control (empty ECIG)
Study: NCT03422419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: transjugular intrahepatic portosystemic shunt deployment
Study: NCT04613154

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesiumcitrate
Description: Magnesiumcitrate 250 mg, Apoteket AB, Sweden

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ester-c
Study: NCT01752660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
Study: NCT01131520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention
Description: This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselor delivered brief intervention
Description: This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
Study: NCT01499784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: behavioral modification and pelvic floor muscle training
Study: NCT01073267

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEBT
Description: Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.